Black Rock Inc. Mesoblast LTD Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.0 - $1.39 $29,885 - $41,540	-29,885 Reduced 66.64%	14,958 $16,000
Q3 2023 Nov 13, 2023	SELL	$1.22 - $4.83 $116,965 - $463,066	-95,873 Reduced 68.13%	44,843 $55,000
Q2 2023 Aug 11, 2023	BUY	$2.95 - $4.44 $168,893 - $254,198	57,252 Added 68.59%	140,716 $550,000
Q1 2023 May 12, 2023	BUY	$2.94 - $4.18 $84,195 - $119,706	28,638 Added 52.23%	83,464 $274,000
Q4 2022 Feb 13, 2023	SELL	$2.73 - $3.7 $2.26 Million - $3.06 Million	-827,057 Reduced 93.78%	54,826 $159,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $3.48 $15,526 - $112,564	32,346 Added 3.81%	881,883 $2.25 Million
Q2 2022 Aug 12, 2022	SELL	$2.22 - $4.54 $33,524 - $68,558	-15,101 Reduced 1.75%	849,537 $1.89 Million
Q1 2022 May 12, 2022	BUY	$3.58 - $4.98 $533,502 - $742,134	149,023 Added 20.82%	864,638 $3.65 Million
Q4 2021 Feb 10, 2022	SELL	$4.17 - $7.09 $383,035 - $651,251	-91,855 Reduced 11.38%	715,615 $3.44 Million
Q3 2021 Nov 09, 2021	BUY	$5.87 - $7.85 $152,807 - $204,351	26,032 Added 3.33%	807,470 $4.85 Million
Q2 2021 Aug 11, 2021	BUY	$6.69 - $9.0 $5.23 Million - $7.03 Million	781,438 New	781,438 $5.85 Million

151K

Ticker MESO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 147,316,000
Market Cap $1.2B
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.